PyInvesting

Market research

LIXT Lixte Biotechnology Holdings Inc

NASDAQ USD Industrials

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
125M
P/E ratio
Not available
Analyst target
Not available
Dividend yield
Not available
Beta
1.25

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Based on the above factors, Lixte Biotechnology Holdings, Inc gets an overall score of 1/5.